Wendy L. Dixon's Insider Trades & SAST Disclosures
Wendy L. Dixon's most recent trade in Zevra Therapeutics Inc was a trade of 39,200 Stock Option (right to buy) done . Disclosure was reported to the exchange on May 13, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Wendy L. Dixon.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zevra Therapeutics Inc | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 39,200 | 39,200 | - | - | Stock Option (right to buy) | |
| Black Diamond Therapeutics... | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 4.54 per share. | 15 Mar 2024 | 3,253 | 38,054 (0%) | 0% | 4.5 | 14,769 | Common Stock |
| Black Diamond Therapeutics... | L. Dixon Wendy | Director | Grant, award, or other acquisition of securities at price $ 2.73 per share. | 15 Dec 2023 | 4,043 | 34,801 (0%) | 0% | 2.7 | 11,037 | Common Stock |
| Black Diamond Therapeutics... | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 2.10 per share. | 16 Jun 2023 | 5,119 | 27,772 (0%) | 0% | 2.1 | 10,750 | Common Stock |
| Arvinas Inc | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 12,787 | 12,787 | - | - | Stock Option (right to buy) | |
| Arvinas Inc | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 4,121 | 9,121 (0%) | 0% | 0 | Common Stock | |
| Black Diamond Therapeutics... | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2023 | 16,500 | 16,500 | - | - | Stock Option (Right to Buy) | |
| Zevra Therapeutics Inc | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2023 | 36,300 | 36,300 | - | - | Stock Option (right to buy) | |
| Zevra Therapeutics Inc | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2023 | 22,500 | 22,500 | - | - | Stock Option (right to buy) | |
| Black Diamond Therapeutics... | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 1.67 per share. | 16 Mar 2023 | 6,437 | 22,653 (0%) | 0% | 1.7 | 10,750 | Common Stock |
| Black Diamond Therapeutics... | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 1.50 per share. | 16 Dec 2022 | 7,167 | 16,216 (0%) | 0% | 1.5 | 10,751 | Common Stock |
| Black Diamond Therapeutics... | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 2.62 per share. | 16 Sep 2022 | 4,103 | 9,049 (0%) | 0% | 2.6 | 10,750 | Common Stock |
| Black Diamond Therapeutics... | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 2.03 per share. | 17 Jun 2022 | 4,946 | 4,946 (0%) | 0% | 2.0 | 10,040 | Common Stock |
| Arvinas Inc | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 10,192 | 10,192 | - | - | Stock Option (right to buy) | |
| Alkermes plc | Wendy L. Dixon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2022 | 7,585 | 53,124 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Wendy L. Dixon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2022 | 7,585 | 0 | - | - | Restricted Stock Unit Award | |
| Iovance Biotherapeutics Inc | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 51,204 | 51,204 | - | - | Deferred Restricted Stock Unit | |
| Black Diamond Therapeutics... | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Apr 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Incyte Corp. | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 79.42 per share. | 31 Mar 2022 | 249 | 17,768 (0%) | 0% | 79.4 | 19,776 | Common Stock |
| Incyte Corp. | Wendy L. Dixon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2021 | 20,000 | 0 | - | - | Non Qualfied Stock Option (right to buy) | |
| Incyte Corp. | Wendy L. Dixon | Director | Sale of securities on an exchange or to another person at price $ 22.05 per share. | 23 Dec 2021 | 20,000 | 17,259 (0%) | 0% | 22.1 | 441,000 | Common Stock |
| Incyte Corp. | Wendy L. Dixon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 73.25 per share. | 23 Dec 2021 | 20,000 | 37,259 (0%) | 0% | 73.3 | 1,465,000 | Common Stock |
| Bluebird bio Inc | Wendy L. Dixon | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 26,361 | 25,953 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Wendy L. Dixon | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 7,500 | 7,384 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Wendy L. Dixon | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 7,500 | 7,384 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Wendy L. Dixon | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 6,241 | 11,894 (0%) | 0% | 0 | Common Stock | |
| Bluebird bio Inc | Wendy L. Dixon | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 5,000 | 10,038 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Wendy L. Dixon | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 4,000 | 3,938 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Wendy L. Dixon | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 4,000 | 3,938 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Wendy L. Dixon | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 4,000 | 3,938 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Wendy L. Dixon | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 4,000 | 3,938 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Wendy L. Dixon | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 3,000 | 2,953 | - | - | Stock Option (right to buy) | |
| Incyte Corp. | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 68.78 per share. | 30 Sep 2021 | 244 | 17,259 (0%) | 0% | 68.8 | 16,782 | Common Stock |
| Incyte Corp. | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 84.13 per share. | 30 Jun 2021 | 214 | 17,015 (0%) | 0% | 84.1 | 18,004 | Common Stock |
| Bluebird bio Inc | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 3,109 | 8,762 (0%) | 0% | 0 | Common Stock | |
| Alkermes plc | Wendy L. Dixon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.21 per share. | 10 Jun 2021 | 25,000 | 66,300 (0%) | 0% | 18.2 | 455,250 | Ordinary Shares |
| Alkermes plc | Wendy L. Dixon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2021 | 25,000 | 0 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Wendy L. Dixon | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 10 Jun 2021 | 25,000 | 41,300 (0%) | 0% | 25 | 625,000 | Ordinary Shares |
| Arvinas Inc | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 7,511 | 7,511 | - | - | Stock Option (right to buy) | |
| Incyte Corp. | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 8,010 | 8,010 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte Corp. | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 1,923 | 16,801 (0%) | 0% | 0 | Common Stock | |
| Alkermes plc | Wendy L. Dixon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2021 | 6,104 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Wendy L. Dixon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2021 | 6,104 | 42,704 (0%) | 0% | 0 | Ordinary Shares | |
| Alkermes plc | Wendy L. Dixon | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.92 per share. | 20 May 2021 | 1,404 | 41,300 (0%) | 0% | 21.9 | 30,776 | Ordinary Shares |
| Alkermes plc | Wendy L. Dixon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.60 per share. | 19 Apr 2021 | 25,000 | 61,600 (0%) | 0% | 14.6 | 365,000 | Ordinary Shares |
| Alkermes plc | Wendy L. Dixon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2021 | 25,000 | 0 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Wendy L. Dixon | Director | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 19 Apr 2021 | 25,000 | 36,600 (0%) | 0% | 20.0 | 500,120 | Ordinary Shares |
| Incyte Corp. | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 81.27 per share. | 31 Mar 2021 | 225 | 14,878 (0%) | 0% | 81.3 | 18,286 | Common Stock |
| Alkermes plc | Wendy L. Dixon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 20,000 | 0 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Wendy L. Dixon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 13 Jan 2021 | 20,000 | 36,600 (0%) | 0% | 12.6 | 252,400 | Ordinary Shares |
| Alkermes plc | Wendy L. Dixon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2021 | 15,000 | 0 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Wendy L. Dixon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 13 Jan 2021 | 15,000 | 16,600 (0%) | 0% | 12.6 | 189,300 | Ordinary Shares |
| Alkermes plc | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2020 | 11,509 | 11,509 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2020 | 5,578 | 5,578 | - | - | Restricted Stock Unit Award | |
| Incyte Corp. | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 89.74 per share. | 30 Sep 2020 | 197 | 14,440 (0%) | 0% | 89.7 | 17,679 | Common Stock |
| Incyte Corp. | Wendy L. Dixon | Director | Sale of securities on an exchange or to another person at price $ 94.51 per share. | 27 Aug 2020 | 20,000 | 14,243 (0%) | 0% | 94.5 | 1,890,200 | Common Stock |
| Incyte Corp. | Wendy L. Dixon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2020 | 20,000 | 0 | - | - | Non Qualfied Stock Option (right to buy) | |
| Incyte Corp. | Wendy L. Dixon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.97 per share. | 27 Aug 2020 | 20,000 | 34,243 (0%) | 0% | 19.0 | 379,400 | Common Stock |
| Incyte Corp. | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 103.97 per share. | 30 Jun 2020 | 182 | 14,243 (0%) | 0% | 104.0 | 18,923 | Common Stock |
| Arvinas Inc | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2020 | 24,000 | 24,000 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 3,000 | 3,000 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 1,500 | 5,653 (0%) | 0% | 0 | Common Stock | |
| Bluebird bio Inc | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 153 | 4,153 (0%) | 0% | 0 | Common Stock | |
| Voyager Therapeutics Inc | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Incyte Corp. | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2020 | 10,514 | 10,514 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte Corp. | Wendy L. Dixon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2020 | 1,282 | 14,061 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges